Shanghai Pharmaceuticals Ownership
| S1R Stock | EUR 1.58 0.01 0.63% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Shanghai |
Shanghai Stock Ownership Analysis
About 22.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Shanghai Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 2.42. The entity last dividend was issued on the 20th of July 2022. Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the Peoples Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical Co., Ltd. SHANGHAI PHARM operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 46609 people. To find out more about Shanghai Pharmaceuticals Holding contact the company at 86 21 6373 0908 or learn more at https://www.sphchina.com.Shanghai Pharmaceuticals Outstanding Bonds
Shanghai Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Shanghai Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Shanghai bonds can be classified according to their maturity, which is the date when Shanghai Pharmaceuticals Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.